Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. reported significant growth in its Cell Processing revenue, achieving $25.3 million, which reflects a 33% year-over-year increase, contributing to a total revenue of $28.1 million for 3Q25 and showcasing 31% year-over-year growth on a proforma basis. The company's ability to report net income of $0.6 million, compared to an anticipated loss, indicates improved financial performance and operational efficiency. Furthermore, management's expectation of maintaining a gross margin in the low-60% range and reducing net loss, alongside a strong cash position, supports a favorable outlook for future growth and sustainability in the cell and gene therapy market.

Bears say

BioLife Solutions faces several fundamental risks that contribute to a negative outlook on its stock, including the potential for lower-than-anticipated growth of its products and services, which is evident from the removal of approximately $8 million in revenue guidance for FY2025. The company is also at risk of not securing additional customers, and it may experience fluctuations in sales in emerging markets due to varying foreign exchange rates. Furthermore, there is a potential dilution risk that could adversely affect existing shareholders, compounding concerns over the company's revenue generation and overall growth prospects.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.